Stanley Nelson, M.D.

Stanley Nelson, MD

Director

About

Stanley F. Nelson, MD is a board certified pediatrician with specific experience with Duchenne muscular dystrophy and rare diseases.  He graduated from University of Michigan with a BS in Physics in 1982. Graduated from Duke University School of Medicine in 1987, and subsequently trained in Pediatrics and Pediatric Hematology-Oncology at UCSF.  He completed postdoctoral fellowship at Stanford University in 1993 before joining the faculty at UCLA. He is Professor of Human Genetics, Pediatrics, Neurology and Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA where he has been faculty since 1993. He is Co-Director of the Clinical Genomics Center, which develops and implements clinical genomic testing and established clinical exome sequencing at UCLA. He is a PI of the Undiagnosed Diseases Network at UCLA which performs discovery of new rare diseases. He is Founder and Co-Director of the Center for Duchenne Muscular Dystrophy which is a multi-investigator program encompassing graduate and undergraduate education, basic and translational research, clinical care, and clinical trials for Duchenne at UCLA. Within the CDMD, he is the Director of the UCLA Certified Duchenne Care Center. His laboratory has published over 280 manuscripts including new analyses of the natural history of Duchenne muscular dystrophy and novel therapeutic strategies. With the UCLA team, he provides care to approximately 200 Duchenne patients in clinic or in clinical trials and is expanding efforts to further improve rare disease diagnosis and translation to novel therapeutics.  

 

Work Titles/Affiliations

  • UCLA Professor In-Residence
  • Human Genetics Director, DNA Microarray Technology
  • Co-Director, Center for Duchenne Muscular Dystrophy Education

Research Interests

Duchenne muscular dystrophy: I lead the Center for Duchenne Muscular DYstrophy which coordinates activities to improve clinical care, clinical trials, education and research related to DMD and serve as a paradigm for progress in rare disease.

Publications